A citation-based method for searching scientific literature

Joshua T Kantrowitz, Daniel C Javitt. Clin Schizophr Relat Psychoses 2010
Times Cited: 79







List of co-cited articles
767 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
17


Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
13



Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients.
Suzie Lavoie, Micah M Murray, Patricia Deppen, Maria G Knyazeva, Michael Berk, Olivier Boulat, Pierre Bovet, Ashley I Bush, Philippe Conus, David Copolov,[...]. Neuropsychopharmacology 2008
265
12

Mismatch negativity in schizophrenia: a meta-analysis.
Daniel Umbricht, Sanya Krljes. Schizophr Res 2005
515
12


D-serine added to antipsychotics for the treatment of schizophrenia.
G Tsai, P Yang, L C Chung, N Lange, J T Coyle. Biol Psychiatry 1998
511
11

Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis.
Karsten Heekeren, Jörg Daumann, Anna Neukirch, Carsten Stock, Wolfram Kawohl, Christine Norra, Till D Waberski, Euphrosyne Gouzoulis-Mayfrank. Psychopharmacology (Berl) 2008
104
11


The positive and negative syndrome scale (PANSS) for schizophrenia.
S R Kay, A Fiszbein, L A Opler. Schizophr Bull 1987
11


Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.
Daniel C Javitt, Stephen R Zukin, Uriel Heresco-Levy, Daniel Umbricht. Schizophr Bull 2012
211
11

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
799
10

High dose D-serine in the treatment of schizophrenia.
Joshua T Kantrowitz, Anil K Malhotra, Barbara Cornblatt, Gail Silipo, Andrea Balla, Raymond F Suckow, Cyril D'Souza, John Saksa, Scott W Woods, Daniel C Javitt. Schizophr Res 2010
160
10

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Robert W Buchanan, Daniel C Javitt, Stephen R Marder, Nina R Schooler, James M Gold, Robert P McMahon, Uriel Heresco-Levy, William T Carpenter. Am J Psychiatry 2007
297
10

Glutamatergic theories of schizophrenia.
Daniel C Javitt. Isr J Psychiatry Relat Sci 2010
187
8

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.
A K Malhotra, D A Pinals, C M Adler, I Elman, A Clifton, D Pickar, A Breier. Neuropsychopharmacology 1997
499
8

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.
John H Krystal, D Cyril D'Souza, Daniel Mathalon, Edward Perry, Aysenil Belger, Ralph Hoffman. Psychopharmacology (Berl) 2003
405
8


D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Uriel Heresco-Levy, Daniel C Javitt, Richard Ebstein, Agnes Vass, Pesach Lichtenberg, Gali Bar, Sara Catinari, Marina Ermilov. Biol Psychiatry 2005
274
8

Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers.
Daniel Umbricht, Rene Koller, Franz X Vollenweider, Liselotte Schmid. Biol Psychiatry 2002
181
8

Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.
John E Lisman, Joseph T Coyle, Robert W Green, Daniel C Javitt, Francine M Benes, Stephan Heckers, Anthony A Grace. Trends Neurosci 2008
726
8


Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.
Joshua T Kantrowitz, Michael L Epstein, Odeta Beggel, Stephanie Rohrig, Jonathan M Lehrfeld, Nadine Revheim, Nayla P Lehrfeld, Jacob Reep, Emily Parker, Gail Silipo,[...]. Brain 2016
55
12

Neural Substrates of Auditory Emotion Recognition Deficits in Schizophrenia.
Joshua T Kantrowitz, Matthew J Hoptman, David I Leitman, Marta Moreno-Ortega, Jonathan M Lehrfeld, Elisa Dias, Pejman Sehatpour, Petri Laukka, Gail Silipo, Daniel C Javitt. J Neurosci 2015
57
12

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.
Michael Berk, David Copolov, Olivia Dean, Kristy Lu, Sue Jeavons, Ian Schapkaitz, Murray Anderson-Hunt, Fiona Judd, Fiona Katz, Paul Katz,[...]. Biol Psychiatry 2008
374
7


Glutamate receptor ion channels: structure, regulation, and function.
Stephen F Traynelis, Lonnie P Wollmuth, Chris J McBain, Frank S Menniti, Katie M Vance, Kevin K Ogden, Kasper B Hansen, Hongjie Yuan, Scott J Myers, Ray Dingledine. Pharmacol Rev 2010
7

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
Gerard J Marek, Berthold Behl, Anton Y Bespalov, Gerhard Gross, Younglim Lee, Hans Schoemaker. Mol Pharmacol 2010
122
7

Effects of ketamine in normal and schizophrenic volunteers.
A C Lahti, M A Weiler, B A Tamara Michaelidis, A Parwani, C A Tamminga. Neuropsychopharmacology 2001
458
7

Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia.
Daniela Alberati, Jean-Luc Moreau, Judith Lengyel, Nicole Hauser, Roland Mory, Edilio Borroni, Emmanuel Pinard, Frederic Knoflach, Götz Schlotterbeck, Dominik Hainzl,[...]. Neuropharmacology 2012
99
7

Effects of clozapine on auditory event-related potentials in schizophrenia.
D Umbricht, D Javitt, G Novak, J Bates, S Pollack, J Lieberman, J Kane. Biol Psychiatry 1998
186
7

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
Daniel Umbricht, Daniela Alberati, Meret Martin-Facklam, Edilio Borroni, Eriene A Youssef, Michael Ostland, Tanya L Wallace, Frédéric Knoflach, Ernest Dorflinger, Joseph G Wettstein,[...]. JAMA Psychiatry 2014
146
7

Mismatch negativity (MMN) as an index of cognitive dysfunction.
Risto Näätänen, Elyse S Sussman, Dean Salisbury, Valerie L Shafer. Brain Topogr 2014
109
7

From perception to functional outcome in schizophrenia: modeling the role of ability and motivation.
Michael F Green, Gerhard Hellemann, William P Horan, Junghee Lee, Jonathan K Wynn. Arch Gen Psychiatry 2012
262
7

Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia.
Michael L Thomas, Michael F Green, Gerhard Hellemann, Catherine A Sugar, Melissa Tarasenko, Monica E Calkins, Tiffany A Greenwood, Raquel E Gur, Ruben C Gur, Laura C Lazzeroni,[...]. JAMA Psychiatry 2017
124
7


Differential relationships of mismatch negativity and visual p1 deficits to premorbid characteristics and functional outcome in schizophrenia.
Tamara Friedman, Pejman Sehatpour, Elisa Dias, Megan Perrin, Daniel C Javitt. Biol Psychiatry 2012
61
9

Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2.
Gregory A Light, Neal R Swerdlow, Michael L Thomas, Monica E Calkins, Michael F Green, Tiffany A Greenwood, Raquel E Gur, Ruben C Gur, Laura C Lazzeroni, Keith H Nuechterlein,[...]. Schizophr Res 2015
110
7

Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Joshua T Kantrowitz, Michael L Epstein, Migyung Lee, Nayla Lehrfeld, Karen A Nolan, Constance Shope, Eva Petkova, Gail Silipo, Daniel C Javitt. Schizophr Res 2018
58
10

Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress.
S Prabakaran, J E Swatton, M M Ryan, S J Huffaker, J T-J Huang, J L Griffin, M Wayland, T Freeman, F Dudbridge, K S Lilley,[...]. Mol Psychiatry 2004
716
6

Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.
Rodrigo D Paz, Sonia Tardito, Marco Atzori, Kuei Y Tseng. Eur Neuropsychopharmacol 2008
86
6

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.
A K Malhotra, D A Pinals, H Weingartner, K Sirocco, C D Missar, D Pickar, A Breier. Neuropsychopharmacology 1996
494
6

Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia.
Daniel Umbricht, Franz X Vollenweider, Liselotte Schmid, Claudia Grübel, Anja Skrabo, Theo Huber, Rene Koller. Neuropsychopharmacology 2003
90
6

Acute dopamine D(1) and D(2) receptor stimulation does not modulate mismatch negativity (MMN) in healthy human subjects.
Sumie Leung, Rodney J Croft, Torsten Baldeweg, Pradeep J Nathan. Psychopharmacology (Berl) 2007
48
10

A theory of cortical responses.
Karl Friston. Philos Trans R Soc Lond B Biol Sci 2005
6

Sensory deficits and distributed hierarchical dysfunction in schizophrenia.
David I Leitman, Pejman Sehatpour, Beth A Higgins, John J Foxe, Gail Silipo, Daniel C Javitt. Am J Psychiatry 2010
88
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.